US Value-Based Management of Oncology Drugs

US Value-Based Management of Oncology Drugs: An Explorative Study of Payer and Provider Tools to Manage the Rising Spending on Oncology Drugs

Oncology and other specialty therapies continue to get more and more expensive for payers, placing immense financial pressure on the HCP. The percentage increase in worldwide spending on oncology medications went up by double digits every year between 2013 and 2018, and reached nearly $150 billion in 2018. Modern cancer therapies significantly improve disease outlook, but with a tremendous cost of treatment.

Read more from Two Lab’s Senior Consultant Anne Runyan about how value-based management of oncology drugs can help mitigate the growing cost of modern cancer treatment. 

We’re here to support your success from clinical to commercial – and beyond.

How can we help you today?